1. Home
  2. BANR vs TRVI Comparison

BANR vs TRVI Comparison

Compare BANR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banner Corporation

BANR

Banner Corporation

HOLD

Current Price

$70.29

Market Cap

2.3B

Sector

Finance

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$17.54

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANR
TRVI
Founded
1890
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.6B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
BANR
TRVI
Price
$70.29
$17.54
Analyst Decision
Hold
Strong Buy
Analyst Count
4
11
Target Price
$70.00
$21.55
AVG Volume (30 Days)
424.7K
3.0M
Earning Date
04-22-2026
05-05-2026
Dividend Yield
3.14%
N/A
EPS Growth
15.57
31.91
EPS
1.60
N/A
Revenue
N/A
N/A
Revenue This Year
$0.73
N/A
Revenue Next Year
$5.69
N/A
P/E Ratio
$43.03
N/A
Revenue Growth
N/A
N/A
52 Week Low
$57.05
$6.55
52 Week High
$72.65
$20.22

Technical Indicators

Market Signals
Indicator
BANR
TRVI
Relative Strength Index (RSI) 57.62 50.62
Support Level $62.97 $10.07
Resistance Level $72.65 $20.19
Average True Range (ATR) 1.57 1.40
MACD -0.00 -0.23
Stochastic Oscillator 60.71 27.89

Price Performance

Historical Comparison
BANR
TRVI

About BANR Banner Corporation

Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: